Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1988 1
1995 3
1996 5
1997 1
1998 1
1999 1
2000 3
2002 3
2003 5
2004 5
2005 7
2006 6
2007 14
2008 12
2009 10
2010 13
2011 12
2012 5
2013 15
2014 10
2015 11
2016 18
2017 10
2018 7
2019 12
2020 14
2021 13
2022 21
2023 8
2024 4
2025 3

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

229 results

Results by year

Filters applied: . Clear all
Page 1
A phase 1 trial of NY-ESO-1-specific TCR-engineered T-cell therapy combined with a lymph node-targeting nanoparticulate peptide vaccine for the treatment of advanced soft tissue sarcoma.
Ishihara M, Nishida Y, Kitano S, Kawai A, Muraoka D, Momose F, Harada N, Miyahara Y, Seo N, Hattori H, Takada K, Emori M, Kakunaga S, Endo M, Matsumoto Y, Sasada T, Sato E, Yamada T, Matsumine A, Nagata Y, Watanabe T, Kageyama S, Shiku H. Ishihara M, et al. Among authors: matsumine a. Int J Cancer. 2023 Jun 15;152(12):2554-2566. doi: 10.1002/ijc.34453. Epub 2023 Feb 17. Int J Cancer. 2023. PMID: 36727538 Clinical Trial.
Safety and Efficacy of NY-ESO-1 Antigen-Specific T-Cell Receptor Gene-Transduced T Lymphocytes in Patients with Synovial Sarcoma: A Phase I/II Clinical Trial.
Kawai A, Ishihara M, Nakamura T, Kitano S, Iwata S, Takada K, Emori M, Kato K, Endo M, Matsumoto Y, Kakunaga S, Sato E, Miyahara Y, Morino K, Tanaka S, Takahashi S, Matsuo F, Matsumine A, Kageyama S, Ueda T. Kawai A, et al. Among authors: matsumine a. Clin Cancer Res. 2023 Dec 15;29(24):5069-5078. doi: 10.1158/1078-0432.CCR-23-1456. Clin Cancer Res. 2023. PMID: 37792433 Free PMC article. Clinical Trial.
The value of trabectedin in the treatment of soft tissue sarcoma.
Nakamura T, Matsumine A, Sudo A. Nakamura T, et al. Among authors: matsumine a. Ther Clin Risk Manag. 2016 Jan 13;12:73-9. doi: 10.2147/TCRM.S84789. eCollection 2016. Ther Clin Risk Manag. 2016. PMID: 26834480 Free PMC article. Review.
The Effect of Static Stretching Duration on Muscle Blood Volume and Oxygenation.
Matsuo H, Kubota M, Shimada S, Kitade I, Matsumura M, Nonoyama T, Koie Y, Naruse H, Takahashi A, Oki H, Kokubo Y, Matsumine A. Matsuo H, et al. Among authors: matsumine a. J Strength Cond Res. 2022 Feb 1;36(2):379-385. doi: 10.1519/JSC.0000000000003457. J Strength Cond Res. 2022. PMID: 32028461
Chimeric antigen receptor T-cell therapy targeting a MAGE A4 peptide and HLA-A*02:01 complex for unresectable advanced or recurrent solid cancer: protocol for a multi-institutional phase 1 clinical trial.
Okumura S, Ishihara M, Kiyota N, Yakushijin K, Takada K, Kobayashi S, Ikeda H, Endo M, Kato K, Kitano S, Matsumine A, Nagata Y, Kageyama S, Shiraishi T, Yamada T, Horibe K, Takesako K, Miwa H, Watanabe T, Miyahara Y, Shiku H. Okumura S, et al. Among authors: matsumine a. BMJ Open. 2022 Nov 14;12(11):e065109. doi: 10.1136/bmjopen-2022-065109. BMJ Open. 2022. PMID: 36375974 Free PMC article.
Bisphosphonate release profiles from magnetite microspheres.
Miyazaki T, Inoue T, Shirosaki Y, Kawashita M, Matsubara T, Matsumine A. Miyazaki T, et al. Among authors: matsumine a. J Biomater Appl. 2014 Oct;29(4):543-7. doi: 10.1177/0885328214536243. Epub 2014 May 21. J Biomater Appl. 2014. PMID: 24854985
229 results